VALPANAT TABLET is a potent combination medication containing Sofosbuvir 400 mg and Velpatasvir 100 mg, designed specifically for the treatment of chronic Hepatitis C Virus (HCV) infection in adults and pediatric patients aged 6 years or older weighing at least 17 kg. This pan-genotypic direct-acting antiviral agent (DAA) delivers high cure rates exceeding 95% by targeting multiple viral replication mechanisms. Sofosbuvir functions as an NS5B polymerase inhibitor, while Velpatasvir acts as an NS5A inhibitor, synergistically halting HCV RNA replication and assembly. The tablet is administered orally once daily, with or without food, typically for a 12-week course. It is effective against all major HCV genotypes (1–6), eliminating the need for genotype-specific therapy in many cases. Additionally, VALPANAT may be combined with ribavirin in patients with cirrhosis for enhanced efficacy. The product requires careful patient screening for hepatitis B to avoid reactivation and cautious use in individuals with severe renal impairment. It is essential to avoid co-administration with strong P-glycoprotein or cytochrome P450 enzyme inducers that can reduce absorption and effectiveness. The tablet is best stored below 30°C in its original packaging to maintain stability.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Sofosbuvir 400 mg + Velpatasvir 100 mg per tablet |
| Drug Class | Direct-acting antiviral agents (DAAs) – NS5B polymerase inhibitor and NS5A inhibitor |
| Indication | Treatment of chronic Hepatitis C Virus (HCV) infection in adults and children ≥6 years or ≥17 kg |
| HCV Genotype Coverage | Pan-genotypic coverage (genotypes 1–6) |
| Dosage | 1 tablet once daily, with or without food for 12 weeks |
| Efficacy | Sustained virologic response (SVR12) rates above 95% |
| Safety Precautions | Screen for hepatitis B virus before treatment; caution in severe renal impairment; avoid during pregnancy especially with ribavirin |
| Drug Interactions | Avoid co-administration with amiodarone, rifampin, carbamazepine, phenytoin, antacids (separate dosing advised) |
| Storage Conditions | Store below 30°C in original container away from moisture |
| Attributes | Description |
|---|---|
| Brand Name | VALPANAT (Natco Pharma) |
| Composition per Tablet | Sofosbuvir 400 mg + Velpatasvir 100 mg |
| Therapeutic Class | Direct-Acting Antiviral Agents |
| Indicated Age Group | Adults and children 6 years and above (≥17 kg) |
| Route of Administration | Oral |
| Treatment Duration | Typically 12 weeks |
| Storage | Below 30°C, protect from moisture |
| Manufacturer | Natco Pharma |
| Packaging | Blister pack / Bottle (as applicable) |
| Contraindications | Pregnancy (especially with ribavirin), severe renal impairment caution |
| Common Side Effects | Fatigue, headache, nausea, insomnia |
| Serious Side Effects | Bradycardia with amiodarone, liver enzyme elevations, hepatitis B reactivation |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Yes, VALPANAT is a pan-genotypic antiviral which is effective against all major Hepatitis C genotypes 1 through 6, eliminating the need for genotype testing before treatment.
Yes, VALPANAT is indicated for use in children aged 6 years or older who weigh at least 17 kg alongside adults for chronic Hepatitis C treatment.
Yes, VALPANAT has significant drug interactions with amiodarone, certain anticonvulsants like carbamazepine and phenytoin, rifampin, and antacids. These can affect the drug’s efficacy or increase side effects, so concurrent use must be carefully managed.
Patients should be screened for Hepatitis B virus infection before starting VALPANAT due to risk of Hepatitis B reactivation. Use with caution in patients with severe renal impairment, and it is generally not recommended during pregnancy, especially when combined with ribavirin.
VALPANAT tablets should be stored at temperatures below 30°C, kept in their original container, and protected from moisture and direct sunlight to maintain stability.
Sofosbuvir + Velpatasvir Tablet – Summary
Brand Names:
VELPANAT (by Natco Pharma)
Epclusa (international brand by Gilead Sciences)
Drug Class:
Direct-Acting Antiviral Agents (DAAs)
NS5B polymerase inhibitor (Sofosbuvir)
NS5A inhibitor (Velpatasvir)
Composition:
Each tablet contains:
Sofosbuvir 400 mg
Velpatasvir 100 mg
Indications / Uses:
Treatment of Chronic Hepatitis C Virus (HCV) infection in adults and children (≥6 years or ≥17 kg)
Effective against all major HCV genotypes (1–6)
Mechanism of Action:
Sofosbuvir inhibits the HCV RNA-dependent RNA polymerase (NS5B), stopping viral replication.
Velpatasvir inhibits the NS5A protein, crucial for viral replication and assembly.
Combined, they block multiple steps in the HCV replication cycle, achieving high cure rates.
Dosage & Administration:
1 tablet once daily with or without food
Duration: Typically 12 weeks
In patients with cirrhosis, ribavirin may be added, depending on the case
Side Effects:
Common:
Fatigue
Headache
Nausea
Insomnia
Serious (rare):
Bradycardia (especially with amiodarone)
Liver enzyme elevations
Reactivation of hepatitis B (in co-infected patients)
Precautions:
Screen for Hepatitis B before initiating treatment
Use caution in severe renal impairment
Not recommended during pregnancy (especially with ribavirin)
Avoid use with strong P-gp or CYP inducers (e.g., rifampin, St. John's Wort)
Drug Interactions:
Amiodarone (risk of serious bradycardia)
Rifampin, carbamazepine, phenytoin (reduce effectiveness)
Antacids (may affect velpatasvir absorption — take separately)
Storage:
Store below 30°C
Keep in original container away from moisture
Effectiveness:
Cure rates (SVR12) above 95% for all HCV genotypes
Pan-genotypic, meaning no need for genotype testing in many cases
Let me know if you'd like a patient-friendly leaflet, PDF summary, or comparison with other Hep C treatments like Sofosbuvir + Daclatasvir.
Ask ChatGPT
